help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Broadus, A. E.
Right arrow Articles by Bartter, F. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Broadus, A. E.
Right arrow Articles by Bartter, F. C.

Journal of Clinical Endocrinology & Metabolism, Vol 47, 751-760, Copyright © 1978 by Endocrine Society


ARTICLES

Pathophysiological studies in idiopathic hypercalciuria: use of an oral calcium tolerance test to characterize distinctive hypercalciuric subgroups

AE Broadus, M Dominguez and FC Bartter

Twenty-one unselected patients with recurrent nephrolithiasis and normocalcemic hypercalciuria with or without hypophosphatemia and 18 normal subjects were studied with an oral calcium tolerance test and for 3- to 5-day periods while consuming a low normal (400 mg) and high- normal (1000 mg) calcium intake. The oral calcium tolerance test consisted of the measurement of the calcemic, calciuric, and parathyroid (assessed by determinations of serum immunoreactive parathyroid hormone and nephrogenous cAMP) responses to acute 1000- or 350-mg doses of calcium. Nineteen patients displayed normal results for basal serum calcium, parathyroid function, and fasting calcium excretion, and striking calcemic (mean increase in serum calcium, 0.9 vs. 0.2 mg/dl in the normal subjects) and calciuric (mean increase in urinary calcium, 0.33 vs. 0.15 mg calcium/100 ml GF in the normal subjects) responses to the 1000-mg calcium tolerance test, associated with a mean 54% suppression in nephrogenous cAMP. These patients were operationally defined as having "absorptive" hypercalciuria. The variable occurrence of hypophosphatemia in this group suggested that the pathogenesis of "absorptive" hypercalciuria may be complex and/or multifactorial. There were strong positive correlations between the calciuric response to the calcium tolerance test and fractional isotopic calcium absorption (r = 0.75, P less than 0.00), the calcemic responses to the test (r = 0.71, P less than 0.001) and the calciuric responses noted on the 1000- vs. the 400-mg daily calcium intake (r = 0.78, P less than 0.001). Two patients displayed low or low normal basal serum calcium, increased parathyroid function, increased fasting calcium excretion, and a striking calciuric but minimal calcemic response to the 1000-mg calcium tolerance test, associated with a moderate suppression in nephrogenous cAMP. These patients were operationally defined as having "renal" hypercalciuria. Several lines of evidence indicated that the hyperparathyroidism in these patients was physiological or secondary, including the near normalization of parathyroid function on the daily 1000-mg calcium intake. A steep slope of calcium excretion on calcium intake (due to increased calcium absorption) was noted in all hypercalciuric patients and accounted for the significantly improved diagnostic accuracy of screening patients for hypercalciuria on the high-normal calcium intake. The simple measurement of total cAMP excretion (nanomoles per 100 ml GF) and urinary calcium on the 1000-mg daily calcium intake seemed to provide reliable separation of patients with "renal" from those with "absorptive" hypercalciuria. A physiological (350 mg) dose of oral calcium produced a 30% suppression of nephrogenous cAMP in normal subjects; this suggests that dietary calcium exerts an important control of parathyroid function under physiological circumstances.


This article has been cited by other articles:


Home page
Am. J. Physiol. Renal Physiol.Home page
E. M. Worcester, D. L. Gillen, A. P. Evan, J. H. Parks, K. Wright, L. Trumbore, Y. Nakagawa, and F. L. Coe
Evidence that postprandial reduction of renal calcium reabsorption mediates hypercalciuria of patients with calcium nephrolithiasis
Am J Physiol Renal Physiol, January 1, 2007; 292(1): F66 - F75.
[Abstract] [Full Text] [PDF]


Home page
J. Nutr.Home page
M. J. Barger-Lux, K. M. Davies, and R. P. Heaney
Calcium Supplementation Does Not Augment Bone Gain in Young Women Consuming Diets Moderately Low in Calcium
J. Nutr., October 1, 2005; 135(10): 2362 - 2366.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
M. J. Favus, A. J. Karnauskas, J. H. Parks, and F. L. Coe
Peripheral Blood Monocyte Vitamin D Receptor Levels Are Elevated in Patients with Idiopathic Hypercalciuria
J. Clin. Endocrinol. Metab., October 1, 2004; 89(10): 4937 - 4943.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Coll. Nutr.Home page
M. Narva, M. Karkkainen, T. Poussa, C. Lamberg-Allardt, and R. Korpela
Caseinphosphopeptides in Milk and Fermented Milk Do Not Affect Calcium Metabolism Acutely in Postmenopausal Women
J. Am. Coll. Nutr., February 1, 2003; 22(1): 88 - 93.
[Abstract] [Full Text] [PDF]


Home page
Arch DermatolHome page
S. A. Leachman, K. L. Insogna, L. Katz, A. Ellison, and L. M. Milstone
Bone Densities in Patients Receiving Isotretinoin for Cystic Acne
Arch Dermatol, August 1, 1999; 135(8): 961 - 965.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1978 by The Endocrine Society